Learning Curve

Public

View Channel

323

2.9K

1.9K

Can't Join? @learnstock_market

162 Members

Updated: May 29, 2026 at 6:35 PM

Learning Curve

This channel is made for educational purposes in terms of stock market learning & understanding. For stock Market latest news and updates join - @stockmarketzilla

@learnstock_market offers specialized information about learning and channel for subscribers interested in Stock Market, Trading & Investment

Ranking

Global Ranking

#49578

-2589

Language Ranking

#8581

-151

Category Ranking

#521

-24

Participant Growth (Last 30 Days)

Total: 162

24h growth: +0 0%

Latest Posts

Learning Curve

Apr 23, 2026, 04:40 PM

A THREAD ON OPTIONS SYNTHETICS:

With synthetics you can increase your returns as the margin requirements/costs are less. Everyone wanting to become a top trader needs to know this and get their concepts cleared because many people don't know what they're doing

Synthetics are formed by the mixture/combinations of any two of the following three.
1. Calls
2. Puts
3. Futures/Stocks

You don't even need to touch futures/stocks. Whatever kind of payoff graph you want, you can get via options only.

Fut buy + Put buy= Call buy
Fut buy + Call sell = Put sell
Fut sell + Call buy = Put Buy
Fut sell + Put sell = Call sell

Fut buy = Call Buy + Put Sell
Fut sell = Put Buy + Call Sell

Know this very well as this is must to know. Now I'll show you how to increase returns.

Synthetics will be used to handle margin requirements better thereby increasing your leverage.

For eg, you want to buy a stock you have to pay huge margin.

Instead of that you can buy an ATM call and sell an ATM put. Margins are drastically lower via options.

We cannot short stocks in India, we need to trade via futures. Some big traders like Sundar Sir, they don't like to trade in futures as they trade via collateral and mtm loss needs to be paid daily. Synthetics take care of that as u only have to pay the loss when booked.

To achieve the collateral benefits plus lower margins, if you want to sell a stock just do the exact reverse of everything I wrote for buying a stock via synthetics.

Selling a stock = Buying puts + Selling Calls.

Payoff graph will be exact same.

Some option sellers claim to understand options very well and they "HATE" option buying. This one's for them.

They say buy fut and buy put for "hedging".

What they fail to realise is actually they've just bought a call via synthetics.

You do what you want but then you cannot be against option buying if you trade in fut and hedge

If you buy a call profit is unlimited, but if no movement occurs then the option will deteriorate in value.

If you buy fut and buy put, and if stock doesn't move, the put goes to zero and fut doesn't give profit.

For Sell fut + buy call just do the reverse i.e. put buy

One more thing irritates me too much. These "covered call" guys fail to realise that they can achieve the same via only selling puts.

They buy fut and sell call to "hedge" paying two margin requirements.

Selling a put requires only one margin.

Opp for covered puts.

I hope I helped you clear some misconceptions/doubts regarding synthetics.

1,780

Learning Curve

Apr 23, 2026, 04:40 PM

Aurobindo Pharma fundamental Analysis

Numbers in line ; US steady despite injectables drop.
Q1FY21 revenues grew 8.8% YoY to 5925 crore mainly due to 15.6% YoY growth in the US to 3107 crore. EU business de-grew 5.0% YoY to 1322 crore. ARV segment grew 33.6% YoY to 426 crore. API segment grew 6.6% YoY to 780 crore. EBITDA margins remained flat YoY at 21.2% as higher gross margins were offset by higher staff costs and other expenditure. EBITDA grew 9.2% YoY to | 1257.4 crore . Adjusted PAT grew 20.4% YoY to | 780.6 crore. EBITDA was due to lower interest cost and higher other income (including | 22.2 crore in forex gain).

US key growth driver despite recent compliance upheavals
After filing its first ANDA in the US in 2003, the company has come a long way as current ANDA filings are at 604. US revenues have grown from ~US$100 million in 2009 crossing $1.6 billion sales as on 2020. In rupee terms, US sales have grown at 17% CAGR to 11484 crore in FY16-20. US formulations now constitute 50% of total turnover, up from 30% in FY13. Despite calling off the acquisition of Sandoz’ US dermatology and oral solid portfolio, we expect US revenue size to reach 14925 crore in FY22E at a 14% CAGR over FY20-22E on the back of a strong US pipeline with 50-60
products expected to be launched in FY21 itself.

Transformation, capacity optimisation to improve financials
The API: formulations ratio has improved from 43:57 in FY13 to 14:86 in FY20. Another USP of the company is its vertically integrated model with huge capacity, unmatched by most peers. The company owns 28 manufacturing facilities, including eight key formulations facilities in India and abroad. These can be optimised by 1) continuous US filings and launches, 2) incremental launches and filings in the RoW markets and 3) sittransfers and supplies for products covered under the Actavis deal.

Valuation & Outlook
FY21 is looking much more promising with respite for unit IV, decent Q1performance and a stable outlook. Aurobindo has one of the best enduring generics ecosystems among peers (vertically integrated model, lower product concentration) to withstand volatility in the US and other generics space. It has also significantly improved its debt position utilising additional cash freed up from foregoing the Sandoz deal. This also bodes well as the company plans to venture into complex areas like biosimilars, vaccines and complex injectables where capital requirements are higher and precise.
While a few other plants still remain under the USFDA scrutiny, the clearance for a critical plant indicates the company continues to work towards stricter adherence.

Aurobindo Pharma is available at cheaper valuation as compared to its peers one can buy for Target price of 1100 at 15x FY22E EPS of | 73.2.

Learning Curve

Apr 23, 2026, 04:40 PM

📷 Photo

565

Learning Curve

Apr 23, 2026, 04:40 PM

pinned Deleted message

Learning Curve

Apr 23, 2026, 04:40 PM

List Of Bullish ChartPattern 👇

*Cup& Handle pattern
*Inverter H&S Pattern
*Ascending Traingle Pattern
*Double bottom Breakout
*Rounding Bottom Breakout
*Falling Wedge Breakout
*Channel Breakout

746

Learning Curve

Apr 23, 2026, 04:40 PM

📷 Photo

730

Learning Curve

Apr 23, 2026, 04:40 PM

📷 Photo

What is circuit filter

484

Learning Curve

Apr 23, 2026, 04:40 PM

📷 Photo

800

Learning Curve

Apr 23, 2026, 04:40 PM

📷 Photo

HIKKAKE CANDLESTICK PATTERN.

The Hikkake pattern pinpoints the failure of inside bar traders.

Trading the break-out of inside bars is a popular strategy. When the break-out fails, we expect the price to blaze in the other direction.

How do we trade it?

We use Hikkake for continuation
Trades.
Buy if a downside break-out of an inside bar fails within three bars

Sell if an upside break-out of an inside bar fails within three bars

687

Learning Curve

Apr 23, 2026, 04:40 PM

📷 Photo

449

Showing 10 of 10 posts

No more posts

Loading posts...

Rating

User Reviews (0)

No reviews yet. Be the first to share your experience!

Loading reviews...

Related Telegram Channels

Loading recommended channels...

Learning Curve

Learning Curve

Ranking

Participant Growth (Last 30 Days)

Latest Posts

Rating

User Reviews (0)

Related Telegram Channels

Business Stock Market Tips💹

UWED FIS (Finance & Investment Society)

MR Stock Option - Best Telegram Channel For Option Trading

Betting Tips King

Artistrajk

GOLDEN ASTRO

Binary options trading signals 2020

Step to Register HF Markets

Related Telegram Channels

Business Stock Market Tips💹

UWED FIS (Finance & Investment Society)

MR Stock Option - Best Telegram Channel For Option Trading

Betting Tips King

Artistrajk

GOLDEN ASTRO

Binary options trading signals 2020

Step to Register HF Markets

User Reviews (0)

Latest Posts